Tscan therapeutics, inc.TCRX.US Overview
TCRX Overall Performance
TCRX AI Analysis & Strategy
TCRX Recent Performance
5.26%
Tscan therapeutics, inc.
0.81%
Avg of Sector
-1.14%
S&P500
TCRX PowerScanner
TCRX Key Information
TCRX Valuation Metrics
TCRX Earnings Table
TCRX Profile
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.